Overview

Yervoy Pregnancy Surveillance Study

Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Ipilimumab